Search
ASH 2025: March Biosciences reported 5 complete responses in all 5 first patients treated in the phase 2 study of its CD5 targeting CAR-T for T-cell lymphoma
Co-Founder and CEO Sarah Hein discusses the CD5 target and this type of cancer, and highlights what is next. March, a startup from the Houston area, has raised over $50 million up to this point. Coverage brought to you by
Dec 8, 2025
Texas Life Science Forum: March Biosciences closed a $28.4M series A round last month to advance its CD5 targeting CAR-T
CEO Sarah Hein describes the rationale for CD5, and share her experience of what it was like making the raise come together. Brought to...
Nov 7, 2024
An entrepreneur describes launching a cell therapy startup in Houston
March Biosciences’ CEO Sarah Hein on the infrastructure available in Houston for biotech startups, and the science behind her CD5 CAR-T.
Sep 23, 2023
.png){kind=logo}
